PharmaJet announced a multi-year agreement with the World Health Organization to provide PharmaJet’s Needle-free technology to be used in the global effort to eradicate polio.
The PharmaJet Tropis Needle-free device has been proven to be safe, fast and easy-to-use with no possibility of needle re-use or needle sticks.
It delivers medications and vaccines intradermally by means of a narrow, high velocity fluid stream, which penetrates the skin and delivers the medicine or vaccine into the dermis.
Because there is no needle, immunizers can work fast and not worry about needles. Additionally, the auto-disabling syringe precludes any possibility of syringe reuse.
“We are pleased that the PharmaJet device will be used for this important activity and we are proud to be part of the global effort to rid our planet of this terrible disease,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
Based in Golden, Colorado, PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. PharmaJet’s devices are also integral in the development of multiple novel pharmaceuticals.
The innovative Stratis Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis® Needle-free Injector was cleared for delivery of an influenza vaccine to deliver needle-free flu shots.
The PharmaJet Tropis device for intradermal injections received authorization to apply the CE Mark in 2016.